TNSN08099A1 - 1-h-imidazopyridines a substituant hydroxy et procedes - Google Patents

1-h-imidazopyridines a substituant hydroxy et procedes

Info

Publication number
TNSN08099A1
TNSN08099A1 TNP2008000099A TNSN08099A TNSN08099A1 TN SN08099 A1 TNSN08099 A1 TN SN08099A1 TN P2008000099 A TNP2008000099 A TN P2008000099A TN SN08099 A TNSN08099 A TN SN08099A TN SN08099 A1 TNSN08099 A1 TN SN08099A1
Authority
TN
Tunisia
Prior art keywords
hydroxy
substituted
methods
compounds
imidazopyridines
Prior art date
Application number
TNP2008000099A
Other languages
English (en)
French (fr)
Inventor
Joseph F Dellaria Jr
William H Moser
Matthew R Radmer
George W Griesgraber
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN08099A1 publication Critical patent/TNSN08099A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TNP2008000099A 2005-09-02 2008-02-29 1-h-imidazopyridines a substituant hydroxy et procedes TNSN08099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71370405P 2005-09-02 2005-09-02
PCT/US2006/034427 WO2007028129A1 (en) 2005-09-02 2006-09-01 Hydroxy substituted 1h-imidazopyridines and methods

Publications (1)

Publication Number Publication Date
TNSN08099A1 true TNSN08099A1 (fr) 2009-07-14

Family

ID=37561219

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000099A TNSN08099A1 (fr) 2005-09-02 2008-02-29 1-h-imidazopyridines a substituant hydroxy et procedes

Country Status (20)

Country Link
US (2) US20100152230A1 (enExample)
EP (1) EP1924581A1 (enExample)
JP (1) JP4584335B2 (enExample)
KR (1) KR20080031496A (enExample)
CN (1) CN101253173A (enExample)
AU (1) AU2006287157A1 (enExample)
BR (1) BRPI0615250A2 (enExample)
CA (1) CA2620933A1 (enExample)
CR (1) CR9781A (enExample)
EA (1) EA200800396A1 (enExample)
EC (1) ECSP088225A (enExample)
IL (1) IL189262A0 (enExample)
MA (1) MA29759B1 (enExample)
MX (1) MX2008002414A (enExample)
NO (1) NO20081393L (enExample)
RS (1) RS20080128A (enExample)
SV (1) SV2009002832A (enExample)
TN (1) TNSN08099A1 (enExample)
WO (1) WO2007028129A1 (enExample)
ZA (1) ZA200801645B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005018556A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AR046172A1 (es) 2003-10-03 2005-11-30 3M Innovative Properties Co Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006028962A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ,インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ[4,5−c]環化合物ならびに方法
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008532933A (ja) 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
EP1850849A2 (en) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
JP2010519186A (ja) 2007-02-19 2010-06-03 スミスクライン ビーチャム コーポレーション 免疫調節物質としてのプリン誘導体
EP1997805A1 (en) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
ATE501136T1 (de) * 2007-08-03 2011-03-15 Pfizer Ltd Imidazopyridinone
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
JP5519670B2 (ja) 2008-08-11 2014-06-11 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
CN102858754A (zh) 2009-08-28 2013-01-02 阵列生物制药公司 Raf抑制剂化合物及其使用方法
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
CN103450198B (zh) * 2012-05-29 2015-07-08 首都医科大学 咪唑并吡啶并咪唑-3-取代乙酸苄酯、其合成、抗肿瘤活性及应用
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 新規化合物
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
CN115151547A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP2023512206A (ja) 2020-01-27 2023-03-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
JP7684316B2 (ja) 2020-01-27 2025-05-27 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115210235A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115279765B (zh) 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
JP7712941B2 (ja) 2020-01-27 2025-07-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
GB202014404D0 (en) 2020-09-14 2020-10-28 Cambridge Entpr Ltd Method for labelling nucleic acid
CN117736210A (zh) * 2021-01-28 2024-03-22 上海翊石医药科技有限公司 一类芳杂环类化合物及其制备方法和用途
CN117466808B (zh) * 2023-12-27 2024-03-12 烟台新药创制山东省实验室 一种6-烷基-2,4-二羟基吡啶类衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0708772T3 (da) * 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
JP4667543B2 (ja) * 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
WO2003103584A2 (en) * 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
JP2005089334A (ja) * 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd 8−ヒドロキシアデニン化合物
WO2005033108A1 (en) * 2003-09-22 2005-04-14 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
AR046781A1 (es) * 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
AU2007216247A1 (en) * 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators

Also Published As

Publication number Publication date
CR9781A (es) 2008-03-26
SV2009002832A (es) 2009-02-19
BRPI0615250A2 (pt) 2011-05-10
JP4584335B2 (ja) 2010-11-17
JP2009507036A (ja) 2009-02-19
ECSP088225A (es) 2008-03-26
KR20080031496A (ko) 2008-04-08
IL189262A0 (en) 2008-06-05
EA200800396A1 (ru) 2008-08-29
NO20081393L (no) 2008-05-28
MA29759B1 (fr) 2008-09-01
ZA200801645B (en) 2010-08-25
US20100152230A1 (en) 2010-06-17
AU2006287157A1 (en) 2007-03-08
MX2008002414A (es) 2008-03-27
US20120035209A1 (en) 2012-02-09
WO2007028129A1 (en) 2007-03-08
EP1924581A1 (en) 2008-05-28
CA2620933A1 (en) 2007-03-08
RS20080128A (sr) 2009-05-06
CN101253173A (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
MA29759B1 (fr) 1h-imidazopyridines a substituant hydroxy et procedes
MY161812A (en) Substituted imidazo ring systems and methods
SG149829A1 (en) Pyrazolopyridines and analogs thereof
BRPI0414856A (pt) imidazoquinolinas alcóxi-substituìdas
TW200639172A (en) Pyrazolopyridines and analogs thereof
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MXPA05009488A (es) 1-amino 1h-imidazoquinolinas.
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MA34308B1 (fr) Triazolopyridines substituées
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
MA28007A1 (fr) Composes organiques
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
TW200510412A (en) Oxime substituted imidazo-containing compounds
MA31754B1 (fr) Cis-imidazolines chirales
WO2006098852A3 (en) Hydroxyalkyl substituted imidazoquinolines
WO2007106854A3 (en) Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
MA31881B1 (fr) Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
WO2006091647A3 (en) Method of preferentially inducing the biosynthesis of interferon
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
MY145983A (en) Aryloxy and arylalkyleneoxy substituted imidazoquinolines
TNSN04168A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
MA29932B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)